Medtronic’s Valiant thoracic stent graft system demonstrates durability after five years


Medtronic has announced favourable five-year data in the VALOR II study, demonstrating the durability of the Valiant thoracic stent graft system, an innovative and minimally invasive treatment for patients with thoracic aortic aneurysms (TAA).

The data, results of five-year patient follow-up, were presented by Mark F Conrad, director of Clinical Research, Division of Vascular and Endovascular Surgery and assistant programme director, Division of Vascular and Endovascular Surgery for Massachusetts General Hospital, USA, at the 42nd Annual Meeting of the New England Society for Vascular Surgery (2–4 October, Newport, USA).

“The five-year results from VALOR II provide confidence to physicians treating patients with descending TAA, in the durability and effectiveness of the Valiant thoracic stent graft system,” said Conrad. “The five-year data demonstrate a high rate of freedom from aneurysm-related mortality and rare incidences of rupture or conversion to open surgery.”

A TAA is a dangerous weakening and subsequent bulge in the aorta close to where it branches off the heart. TAAs that rupture usually result in death. An estimated 60,000 people in the USA alone have a TAA. Those aneurysms that are detected before rupturing can usually be effectively treated with stent grafts or invasive surgery.

VALOR II is a prospective, single-arm study that involved 160 patients at 24 US medical centres. It was designed to evaluate the safety and effectiveness of the Valiant system for thoracic endovascular aortic repair (TEVAR) of aneurysms in the descending thoracic aorta.

Key VALOR II five-year follow-up findings include:

  • 94.8% freedom from aneurysm related mortality
  • 1.3% rupture rate
  • 6.9% required secondary procedures
  • 0.6% (1/160) conversion to open surgery rate
  • 89.3% of patients had stable or decreased aneurysm size
  • 0% migration reported (defined as >10mm from the one-month follow-up)
  • 0% loss of integrity reported.

The Valiant system is indicated for the endovascular repair of all lesions of the descending thoracic aorta in patients having appropriate anatomy, including: iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories, non-aneurysmal aortic diameter in the range of 18–42mm and non-aneurysmal aortic proximal and distal neck lengths >=20mm.